Candel Therapeutics announced the publication of final Phase 2a clinical trial results for aglatimagene besadenovec in NSCLC patients, showing a median overall survival of 24.5 months. This positive data could significantly impact the company's valuation and future development plans for the drug.
Candel Therapeutics has published the final results of its Phase 2a clinical trial for aglatimagene besadenovec (agla) in combination with valacyclovir for patients with Stage III/IV NSCLC who had an inadequate response to immune checkpoint inhibitors (ICI). The key finding is a median overall survival of 24.5 months, which is a significant outcome for this difficult-to-treat patient population. This positive data could lead to increased investor confidence in CADL, potentially driving its stock price higher in the short term. Long-term implications include the potential for further clinical development and eventual market approval, which would be a major revenue driver for the company. The primary risk is that these results are from a Phase 2a trial, and success in later-stage trials is not guaranteed.